A fully caninised anti-NGF monoclonal antibody for pain relief in dogs.

ABSTRACT:

Background

Monoclonal antibodies are a major class of biological therapies in human medicine but have not yet been successfully applied to veterinary species. We have developed a novel approach, PETisation, to rapidly convert antibodies for use in veterinary species. As an example, anti-nerve growth factor (anti-NGF) monoclonal antibodies (mAbs) which are effective in reducing acute and chronic pain in rodents and man are potentially useful for treating pain in dogs but a fully caninised mAb is required in order to avoid an immune response. The aim of this study was to determine the optimal properties of a caninised anti-NGF mAb for safe, repeated administration to dogs, to determine its pharmacokinetic properties and to evaluate its efficacy in a model of inflammatory pain in vivo

SUBMITTER: Gearing DP 

PROVIDER: S-EPMC3834884 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature